Villya Enters Hemp-Derived THC Beverage Market Through Acquisition of Hythlayn Patent

Villya's Solubility Technology at work

The molecule that will change the drink industry

This is the next thing in the drink industry

Villya targets one exclusive global beverage partner for its fast-acting, homogeneous and shelf-stable patented cannabinoid technology.

MELBOURNE, FL, UNITED STATES, August 12, 2026 /EINPresswire.com/ -- Villya Pharmaceuticals today announced its entry into the hemp-derived THC beverage market through the acquisition of Hythlayn Inc.'s cannabinoid intellectual property, including international patent application WO2025059525A1, “Compositions and Methods for Improving the Solubility of Cannabinoids and Endocannabinoids.” The acquisition positions Villya as a technology and intellectual-property company within the rapidly evolving market for hemp-derived Delta-9 THC beverages, THC seltzers, cannabis drinks and next-generation adult beverages. Villya does not intend to manufacture beverages.

Instead, the company intends to pursue an exclusive licensing relationship with one major global beverage company capable of commercializing the technology at scale.

Solving One of THC's Fundamental Problems

Delta-9 THC is highly hydrophobic, creating significant challenges when incorporating the cannabinoid into water-based beverages.

Villya's newly acquired intellectual property is directed toward improving the solubility of cannabinoids and endocannabinoids, creating potential applications across beverages and other cannabinoid-delivery formats.

In Villya testing, its proprietary THC technology has demonstrated a combination of characteristics the company believes could be particularly important to the beverage industry:
Approximately 3–4 minute onset.
Homogeneous cannabinoid distribution.
Shelf-stable formulations without the cannabinoid falling out of solution.
Approximately 24-hour clearance observed in Villya testing.
Villya believes the combination of rapid onset, cannabinoid solubility, formulation stability, consistent dosing and rapid clearance could create a fundamentally different consumer experience from traditional edible cannabinoid products.

Built for the Beverage Industry Villya's strategy is deliberate.

The company does not intend to build bottling plants, establish beverage distribution networks or compete with established beer, wine and spirits companies.

Those capabilities already exist at enormous global scale. Villya intends to provide something different: The intellectual property and cannabinoid-delivery technology inside the beverage. For the right global beverage company, an exclusive license could provide access to differentiated technology for developing fast-acting THC beverages, Delta-9 THC drinks, cannabis beverages and next-generation adult beverage alternatives, subject to applicable regulatory requirements. Villya intends to evaluate strategic relationships and ultimately select one major beverage partner for an exclusive licensing opportunity within the defined beverage category.

A Major Federal Deadline Is Approaching

Villya's entry into the market comes at a pivotal moment for the U.S. hemp-derived cannabinoid industry. On November 12, 2026, a new federal definition of hemp is scheduled to take effect, substantially changing the regulatory framework that helped create today's hemp-derived THC consumer market.

Under the amended definition, final hemp-derived cannabinoid products containing greater than 0.4 milligrams combined total THC and cannabinoids with similar effects per container would be excluded from the federal definition of hemp. The change could dramatically reshape today's hemp-derived Delta-9 THC beverage market. Villya believes this approaching regulatory transition makes sophisticated cannabinoid technology, intellectual property, formulation science and regulatory strategy increasingly important. The company does not claim that its technology circumvents federal or state THC restrictions. Instead, Villya intends to work with a major beverage organization capable of evaluating compliant commercialization pathways as federal and state cannabinoid regulations evolve. Villya's intellectual property is centered on cannabinoid solubility and delivery, rather than dependence upon any single regulatory classification. As the regulatory landscape changes, Villya believes ownership of differentiated cannabinoid-delivery technology could become increasingly valuable.

From 3–4 Minutes to Approximately 24 Hours

The potential consumer experience represents another major component of Villya's technology.
Villya has observed effects beginning in approximately three to four minutes in testing of its proprietary THC formulation. At the other end of the pharmacokinetic profile, the company has observed clearance from the user's system within approximately 24 hours in its testing. Villya believes the combination of rapid onset and observed rapid clearance warrants continued scientific and commercial investigation and could become an important differentiator for future cannabinoid beverages. Individual metabolism, dosage, frequency of use, physiology and drug-testing methodology can influence THC detection. Villya therefore does not represent that use of a Villya-formulated product guarantees an individual will pass a particular drug test.

One Technology. One Global Beverage Partner

The world's largest beverage companies have spent generations perfecting brands, manufacturing, packaging, distribution and consumer experiences.
Cannabinoids introduce a different challenge: Delivery technology. Villya believes its acquired intellectual property could provide a major beverage company with a differentiated technology platform for participating in whatever the next generation of regulated cannabinoid beverages becomes.

The company's strategy is intentionally selective. Villya does not intend to broadly license its beverage technology across competing global beverage companies. Instead, Villya intends to identify one global partner with the resources, brands, distribution infrastructure and vision necessary to commercialize the technology at scale. For major beer, spirits and beverage companies evaluating the future of THC beverages, hemp-derived Delta-9, cannabis drinks, functional beverages and alcohol alternatives, Villya believes the opportunity extends beyond launching another beverage.

It is an opportunity to license the underlying technology. Villya owns the technology. Its future beverage partner brings the scale.

About Villya Pharmaceuticals

Villya Pharmaceuticals is a pharmaceutical technology and intellectual-property company developing proprietary technologies designed to improve the solubility, stability, bioavailability and delivery of difficult-to-formulate molecules.

With the acquisition of Hythlayn's cannabinoid intellectual property, Villya is expanding its technology platform into the evolving cannabinoid and hemp-derived THC beverage markets while pursuing strategic licensing opportunities with global industry partners.

website: www.villya.net
email: info@villya.net
Linkedin: https://www.linkedin.com/company/villya/?viewAsMember=true

*Images generated by chatgpt

William Miller
Villya
info@Villya.net
Visit us on social media:
LinkedIn
Instagram